Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

More Research Required to Determine Best Practices in High-Risk Myeloma

February 27th 2020

Andrew Branagan, MD, discusses the evolving role of transplant and ongoing research in high-risk multiple myeloma.

Selinexor Offers Patients New Path in Relapsed/Refractory Myeloma

February 27th 2020

Robb S. Friedman, MD, shares insight on the emergence of selinexor in the treatment paradigm for patients with relapsed/refractory multiple myeloma.

Dr. Kumar on the Role of Stem Cell Mobilization in Multiple Myeloma

February 21st 2020

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.

The Potential Utility of CLR 131 in Multiple Myeloma

February 19th 2020

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Dr. Costello on the Future of Isatuximab in Relapsed/Refractory Multiple Myeloma

February 18th 2020

Caitlin Costello, MD, discusses the future of isatuximab in relapsed/refractory multiple myeloma.

Daratumumab Becomes Treatment Staple in Newly Diagnosed Multiple Myeloma

February 14th 2020

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.

Dr. Usmani on Situations that Indicate the Need for Immediate Treatment in R/R Multiple Myeloma

February 14th 2020

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

Navigating Triplet Therapies in Relapsed/Refractory Multiple Myeloma

February 14th 2020

Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.

Phasing Out Doublet Regimens in Relapsed/Refractory Multiple Myeloma

February 12th 2020

Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma.

Dr. Paul on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

February 12th 2020

Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.

FDA Approval Sought for Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma

February 11th 2020

A supplemental Biologics License Application has been submitted to the FDA for daratumumab for use in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Atrash on Investigational Combinations With Venetoclax in Relapsed/Refractory Multiple Myeloma

February 11th 2020

Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

Novel Agents Move Through Relapsed/Refractory Myeloma Pipeline

February 10th 2020

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

CAR-T Paving New Path in Relapsed/Refractory Myeloma

February 7th 2020

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Dr. Shah on Potential for Daratumumab Maintenance in Multiple Myeloma

February 7th 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential for daratumumab (Darzalex) maintenance therapy in multiple myeloma.

JNJ-4528 Boasts High Response Rate in Relapsed/Refractory Myeloma

February 6th 2020

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Dr. Usmani on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

February 6th 2020

Saad Z. Usmani, MD, FACP, discusses treatment considerations in relapsed/refractory multiple myeloma.

Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

February 5th 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Dr. Atrash on the BELLINI Trial Results in Relapsed/Refractory Multiple Myeloma

February 4th 2020

Shebli Atrash, MD, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Myeloma Application Fast-Tracked in EU

February 3rd 2020

The European Medicines Agency has validated a Marketing Authorization Application for belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody.